Literature DB >> 15189359

Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice.

Anke Witting1, Patrick Weydt, Soyon Hong, Michel Kliot, Thomas Moller, Nephi Stella.   

Abstract

Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene and transgenic mice for these mutations recapitulate many features of this devastating neurodegenerative disease. Here we show that the amount of anandamide (AEA) and 2-arachidonoylglycerol (2-AG), two endocannabinoids that have neuroprotective properties, increase in spinal cord of SOD1(G93A) transgenic mice. This increase occurs in the lumbar section of spinal cords, the first section to undergo neurodegeneration, and is significant before overt motor impairment. Our results show that chronic neurodegeneration induced by a genetic mutation increases endocannabinoid production possibly as part of an endogenous defense mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189359     DOI: 10.1111/j.1471-4159.2004.02544.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  25 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Dosing medical marijuana: rational guidelines on trial in Washington State.

Authors:  Sunil K Aggarwal; Muraco Kyashna-Tocha; Gregory T Carter
Journal:  MedGenMed       Date:  2007-09-11

Review 5.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

Review 6.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

Review 7.  Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

Authors:  Francisco Espejo-Porras; Fabiana Piscitelli; Roberta Verde; José A Ramos; Vincenzo Di Marzo; Eva de Lago; Javier Fernández-Ruiz
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-29       Impact factor: 4.147

8.  Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.

Authors:  Carmen Rodríguez-Cueto; Cristina Benito; Javier Fernández-Ruiz; Julián Romero; Mariluz Hernández-Gálvez; María Gómez-Ruiz
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

Authors:  Giulio G Muccioli; Nephi Stella
Journal:  Anal Biochem       Date:  2007-09-29       Impact factor: 3.365

Review 10.  Role of cannabinoids and endocannabinoids in cerebral ischemia.

Authors:  Cecilia J Hillard
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.